In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
After finishing at $25.98 in the prior trading day, Summit Therapeutics Inc (NASDAQ: SMMT) closed at $19.44, down -25.15%. In other words, the price has decreased by -$25.15 from its previous closing price. On the day, 16.12 million shares were traded. SMMT stock price reached its highest trading level at $22.78 during the session, while it also had its lowest trading level at $19.1.
Ratios:
Our goal is to gain a better understanding of SMMT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.13 and its Current Ratio is at 5.13. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 04, 2025, initiated with a Buy rating and assigned the stock a target price of $40.
On August 19, 2025, Piper Sandler started tracking the stock assigning a Neutral rating and target price of $21. On July 01, 2025, UBS started tracking the stock assigning a Buy rating and target price of $30.UBS initiated its Buy rating on July 01, 2025, with a $30 target price.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SMMT now has a Market Capitalization of 14444659712 and an Enterprise Value of 14152334336.
Stock Price History:
The Beta on a monthly basis for SMMT is -1.10, which has changed by -0.15346104 over the last 52 weeks, in comparison to a change of 0.18189907 over the same period for the S&P500. Over the past 52 weeks, SMMT has reached a high of $36.91, while it has fallen to a 52-week low of $11.88. The 50-Day Moving Average of the stock is -24.33%, while the 200-Day Moving Average is calculated to be -11.89%.
Shares Statistics:
The stock has traded on average 3.34M shares per day over the past 3-months and 4631180 shares per day over the last 10 days, according to various share statistics. A total of 742.81M shares are outstanding, with a floating share count of 112.12M. Insiders hold about 84.90% of the company’s shares, while institutions hold 13.28% stake in the company. Shares short for SMMT as of 1755216000 were 29812741 with a Short Ratio of 8.92, compared to 1752537600 on 28557957. Therefore, it implies a Short% of Shares Outstanding of 29812741 and a Short% of Float of 25.52.
Earnings Estimates
A detailed examination of Summit Therapeutics Inc (SMMT) is currently in progress, with 9.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.07 and low estimates of -$0.57.
Analysts are recommending an EPS of between $0.08 and -$1.75 for the fiscal current year, implying an average EPS of -$0.7. EPS for the following year is -$0.7, with 8.0 analysts recommending between -$0.3 and -$2.54.
Revenue Estimates
Based on 12 analysts’ estimates, the company’s revenue will be $3.94M in the next fiscal year. The high estimate is $42.85M and the low estimate is -$42.09M.